Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP28 | Q96RU2 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | MPO | P05164 | 4/20 | 0.34 |
| ▸ | BACE1 | P56817 | 4/20 | 0.34 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18235895 | 0.86 | MAOA (0.36) | USP28MAOAMAOBDPP4KMT2A | |
| SCHEMBL10045212 | 0.81 | USP28 (0.40) | USP28SLC6A4MPOBACE1BACE2 | |
| SCHEMBL4630473 | 0.79 | ACHE (0.48) | MAOAMAOBSMN1; SMN2MPO | |
| SCHEMBL21171674 | 0.77 | SLC6A4 (0.47) | MAOAMAOBKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL19102996 | 0.76 | SMN1; SMN2 (0.41) | KMT2AMEN1SMN1; SMN2SLC6A4MPO | |
| SCHEMBL13535945 | 0.76 | USP28 (0.44) | USP28MAOAMAOBKMT2AMEN1 | |
| SCHEMBL21674321 | 0.73 | MPO (0.59) | KMT2AMEN1SMN1; SMN2SLC6A4MPO | |
| SCHEMBL19954239 | 0.73 | ADRB2 (0.51) | KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL7142605 | 0.73 | S1PR1 (0.40) | USP28KMT2A | |
| SCHEMBL24709706 | 0.73 | DPP4 (0.42) | USP28DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100076024-A1 | Novel Compounds as Serine Protease Inhibitors | ZIMMERMANN KASPAR | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076024-A1 | Novel Compounds as Serine Protease Inhibitors | PRSS1, SERPINB1, SPINT2 | USP28 827/4885MAOA 1790/4885MAOB 1747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.